Connext Raises $10M Series C for Regenerative Therapy

South Korean biopharmaceutical firm Connext has successfully closed a $10.02 million Series C funding round, injecting crucial capital to propel its lead regenerative medicine candidate, CNT201, through advanced clinical trials and toward global commercialization. The financing round saw robust participation from both existing and new investors, underscoring confidence in the company's innovative pipeline.

A significant development in this round is the strategic investment from PharmaResearch, a company recognized for its expertise in regenerative medicine and established international commercial infrastructure. This partnership transcends their prior licensing agreement for CNT201, evolving into an equity-based, long-term alliance. The collaboration is designed to leverage Connext's proficiency in recombinant protein research, development, and manufacturing alongside PharmaResearch's global market access. Their joint strategy aims to expedite the successful market introduction of CNT201, explore additional therapeutic applications such as cellulite treatment, and jointly develop next-generation protein-based biotherapeutics.

The newly acquired funds will be strategically allocated to accelerate the development of CNT201 and bolster the company's broader pipeline. Connext plans to finalize its Phase 2 clinical trial in Australia for Dupuytren's contracture, initiate the manufacturing of materials for Phase 3 trials, and commence early-stage clinical investigations for the cellulite indication. With a clear focus on addressing significant unmet medical needs, particularly as an alternative to surgical interventions, the company intends to aggressively pursue global business development opportunities following positive Phase 2 results.

The investor syndicate for this Series C round includes returning supporter ES Investor, alongside new financial backers Premier Partners, Murex Partners, Soo Investment Capital, and The Next Lab. This diverse group of investors highlights a broad market appetite for promising biotechnology ventures, even amidst a competitive funding environment.

Mun Se-young, Managing Director at ES Investor, expressed strong conviction in the asset's potential, noting, "CNT201 presents as a best-in-class candidate, offering distinct advantages over existing treatments like Xiaflex, which shares a similar mechanism of action. We anticipate substantial global market success, driven by its superior formulation and demonstrated clinical benefits."

Woo-jong Lee, CEO of Connext, emphasized the funding's significance as a market validation. "Securing this Series C in the current challenging biotech investment climate is a clear endorsement of our pipeline's differentiated technology and commercial viability," stated Lee. "With the unwavering support of our financial and strategic partners, we are dedicated to completing our Phase 2 trial in Australia and establishing Connext as a leading global biotechnology enterprise." The company's participation in the Seoul BioHub's “2026 BIO USA Support Program” and its planned investor outreach at the BIO International Convention in San Diego further signal its proactive approach to global expansion and partnership building.